Biogen Gains Rare Retinal Disorder Treatment With Nightstar Acquisition

Biogen completed its $800 million acquisition of clinical-stage gene therapy company Nightstar Therapeutics.

With the addition of Nightstar, Biogen acquires NSR-REP1, a treatment for choroideremia, a rare, degenerative retinal disorder that leads to blindness and has no approved treatments.

“We look forward to working now as one Biogen team with the goal of bringing breakthrough therapies to patients to slow or halt blindness across a range of inherited retinal diseases,” said Biogen CEO Michel Vounatsos.